Takeda's stem cell ther­a­py flunks PhI­II test study­ing the drug in Crohn's dis­ease

Take­da’s al­lo­gene­ic stem cell ther­a­py flunked a Phase III study for the treat­ment of a com­mon com­pli­ca­tion of Crohn’s dis­ease, ac­cord­ing to topline da­ta af­ter 24 weeks.

Take­da did not re­lease de­tailed da­ta from the tri­al of dar­vad­stro­cel, mar­ket­ed as Alofisel, on Tues­day, but said that it was “con­tin­u­ing to as­sess the fi­nan­cial im­pacts of the study re­sults, in­clud­ing im­pair­ment loss for in­tan­gi­ble as­sets” for the quar­ter that end­ed Sept. 30.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.